MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584792 | Name: MIV 150

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MIV 150 is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that has been found effective against simian-human immunodeficiency virus-RT (SHIV-RT).

Chemical Structure

MIV 150
MIV 150
CAS#231957-54-3

Theoretical Analysis

MedKoo Cat#: 584792

Name: MIV 150

CAS#: 231957-54-3

Chemical Formula: C19H17FN4O3

Exact Mass: 368.1285

Molecular Weight: 368.37

Elemental Analysis: C, 61.95; H, 4.65; F, 5.16; N, 15.21; O, 13.03

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
MIV 150; MIV-150; PC 815
IUPAC/Chemical Name
1-(5-cyanopyridin-2-yl)-3-((1S,2S)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl)urea
InChi Key
NKPHEWJJTGPRSL-OCCSQVGLSA-N
InChi Code
InChI=1S/C19H17FN4O3/c1-2-15(25)11-4-5-13(20)17(18(11)26)12-7-14(12)23-19(27)24-16-6-3-10(8-21)9-22-16/h3-6,9,12,14,26H,2,7H2,1H3,(H2,22,23,24,27)/t12-,14+/m1/s1
SMILES Code
O=C(N[C@@H]1[C@H](C2=C(F)C=CC(C(CC)=O)=C2O)C1)NC3=NC=C(C#N)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 368.37 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mizenina O, Hsu M, Jean-Pierre N, Aravantinou M, Levendosky K, Paglini G, Zydowsky TM, Robbiani M, Fernández-Romero JA. MIV-150 and zinc acetate combination provides potent and broad activity against HIV-1. Drug Deliv Transl Res. 2017 Dec;7(6):859-866. doi: 10.1007/s13346-017-0421-4. PubMed PMID: 28812250. 2: Ouattara LA, Barnable P, Mawson P, Seidor S, Zydowsky TM, Kizima L, Rodriguez A, Fernández-Romero JA, Cooney ML, Roberts KD, Gettie A, Blanchard J, Robbiani M, Teleshova N. MIV-150-containing intravaginal rings protect macaque vaginal explants against SHIV-RT infection. Antimicrob Agents Chemother. 2014 May;58(5):2841-8. doi: 10.1128/AAC.01529-13. Epub 2014 Mar 10. PubMed PMID: 24614384; PubMed Central PMCID: PMC3993268. 3: Giacobbi NS, Sluis-Cremer N. In Vitro Cross-Resistance Profiles of Rilpivirine, Dapivirine, and MIV-150, Nonnucleoside Reverse Transcriptase Inhibitor Microbicides in Clinical Development for the Prevention of HIV-1 Infection. Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00277-17. doi: 10.1128/AAC.00277-17. Print 2017 Jul. PubMed PMID: 28507107; PubMed Central PMCID: PMC5487620. 4: Friedland BA, Hoesley CJ, Plagianos M, Hoskin E, Zhang S, Teleshova N, Alami M, Novak L, Kleinbeck KR, Katzen LL, Zydowsky TM, Fernández-Romero JA, Creasy GW. First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics. J Acquir Immune Defic Syndr. 2016 Dec 15;73(5):489-496. PubMed PMID: 27437826; PubMed Central PMCID: PMC5172848. 5: Barnable P, Calenda G, Ouattara L, Gettie A, Blanchard J, Jean-Pierre N, Kizima L, Rodríguez A, Abraham C, Menon R, Seidor S, Cooney ML, Roberts KD, Sperling R, Piatak M Jr, Lifson JD, Fernandez-Romero JA, Zydowsky TM, Robbiani M, Teleshova N. A MIV-150/zinc acetate gel inhibits SHIV-RT infection in macaque vaginal explants. PLoS One. 2014 Sep 26;9(9):e108109. doi: 10.1371/journal.pone.0108109. eCollection 2014. PubMed PMID: 25259616; PubMed Central PMCID: PMC4178065. 6: Barnable P, Calenda G, Bonnaire T, Menon R, Levendosky K, Gettie A, Blanchard J, Cooney ML, Fernández-Romero JA, Zydowsky TM, Teleshova N. MIV-150/zinc acetate gel inhibits cell-associated simian-human immunodeficiency virus reverse transcriptase infection in a macaque vaginal explant model. Antimicrob Agents Chemother. 2015 Jul;59(7):3829-37. doi: 10.1128/AAC.00073-15. Epub 2015 Apr 13. PubMed PMID: 25870063; PubMed Central PMCID: PMC4468722. 7: Fernández-Romero JA, Thorn M, Turville SG, Titchen K, Sudol K, Li J, Miller T, Robbiani M, Maguire RA, Buckheit RW Jr, Hartman TL, Phillips DM. Carrageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis. 2007 Jan;34(1):9-14. PubMed PMID: 16924181. 8: Hsu M, Keele BF, Aravantinou M, Krawczyk N, Seidor S, Abraham CJ, Zhang S, Rodriguez A, Kizima L, Derby N, Jean-Pierre N, Mizenina O, Gettie A, Grasperge B, Blanchard J, Piatak MJ Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M. Exposure to MIV-150 from a high-dose intravaginal ring results in limited emergence of drug resistance mutations in SHIV-RT infected rhesus macaques. PLoS One. 2014 Feb 27;9(2):e89300. doi: 10.1371/journal.pone.0089300. eCollection 2014. PubMed PMID: 24586674; PubMed Central PMCID: PMC3937329. 9: Singer R, Mawson P, Derby N, Rodriguez A, Kizima L, Menon R, Goldman D, Kenney J, Aravantinou M, Seidor S, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Robbiani M, Zydowsky TM. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med. 2012 Sep 5;4(150):150ra123. doi: 10.1126/scitranslmed.3003936. PubMed PMID: 22956201; PubMed Central PMCID: PMC4391747. 10: Singer R, Derby N, Rodriguez A, Kizima L, Kenney J, Aravantinou M, Chudolij A, Gettie A, Blanchard J, Lifson JD, Piatak M Jr, Fernández-Romero JA, Zydowsky TM, Robbiani M. The nonnucleoside reverse transcriptase inhibitor MIV-150 in carrageenan gel prevents rectal transmission of simian/human immunodeficiency virus infection in macaques. J Virol. 2011 Jun;85(11):5504-12. doi: 10.1128/JVI.02422-10. Epub 2011 Mar 16. PubMed PMID: 21411526; PubMed Central PMCID: PMC3094984. 11: Kenney J, Singer R, Derby N, Aravantinou M, Abraham CJ, Menon R, Seidor S, Zhang S, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero JA, Zydowsky TM, Robbiani M. A single dose of a MIV-150/Zinc acetate gel provides 24 h of protection against vaginal simian human immunodeficiency virus reverse transcriptase infection, with more limited protection rectally 8-24 h after gel use. AIDS Res Hum Retroviruses. 2012 Nov;28(11):1476-84. doi: 10.1089/AID.2012.0087. Epub 2012 Jul 30. PubMed PMID: 22737981; PubMed Central PMCID: PMC3484818. 12: Aravantinou M, Singer R, Derby N, Calenda G, Mawson P, Abraham CJ, Menon R, Seidor S, Goldman D, Kenney J, Villegas G, Gettie A, Blanchard J, Lifson JD, Piatak M Jr, Fernández-Romero JA, Zydowsky TM, Teleshova N, Robbiani M. The nonnucleoside reverse transcription inhibitor MIV-160 delivered from an intravaginal ring, but not from a carrageenan gel, protects against simian/human immunodeficiency virus-RT Infection. AIDS Res Hum Retroviruses. 2012 Nov;28(11):1467-75. doi: 10.1089/AID.2012.0080. Epub 2012 Aug 27. PubMed PMID: 22816564; PubMed Central PMCID: PMC3484820. 13: Villegas G, Calenda G, Ugaonkar S, Zhang S, Kizima L, Mizenina O, Gettie A, Blanchard J, Cooney ML, Robbiani M, Fernández-Romero JA, Zydowsky TM, Teleshova N. A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo. PLoS One. 2016 Jul 18;11(7):e0159332. doi: 10.1371/journal.pone.0159332. eCollection 2016. PubMed PMID: 27428377; PubMed Central PMCID: PMC4948912. 14: Calenda G, Villegas G, Barnable P, Litterst C, Levendosky K, Gettie A, Cooney ML, Blanchard J, Fernández-Romero JA, Zydowsky TM, Teleshova N. MZC Gel Inhibits SHIV-RT and HSV-2 in Macaque Vaginal Mucosa and SHIV-RT in Rectal Mucosa. J Acquir Immune Defic Syndr. 2017 Mar 1;74(3):e67-e74. doi: 10.1097/QAI.0000000000001167. PubMed PMID: 27552154; PubMed Central PMCID: PMC5303173. 15: Jean-Pierre N, Barnable P, Kizima L, Rodríguez A, Seidor S, Cooney ML, Clark MR, Doncel GF, Robbiani M, Zydowsky TM, Teleshova N, Fernández-Romero JA. Multipurpose Prevention Approaches with Antiretroviral-Based Formulations. Antimicrob Agents Chemother. 2015 Nov 23;60(2):1141-4. doi: 10.1128/AAC.02468-15. Print 2016 Feb. PubMed PMID: 26596943; PubMed Central PMCID: PMC4750675. 16: Derby N, Aravantinou M, Kenney J, Ugaonkar SR, Wesenberg A, Wilk J, Kizima L, Rodriguez A, Zhang S, Mizenina O, Levendosky K, Cooney ML, Seidor S, Gettie A, Grasperge B, Blanchard J, Piatak M Jr, Lifson JD, Fernández-Romero J, Zydowsky TM, Robbiani M. An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques. Drug Deliv Transl Res. 2017 Dec;7(6):840-858. doi: 10.1007/s13346-017-0389-0. PubMed PMID: 28600625; PubMed Central PMCID: PMC5656733. 17: Ugaonkar SR, Wesenberg A, Wilk J, Seidor S, Mizenina O, Kizima L, Rodriguez A, Zhang S, Levendosky K, Kenney J, Aravantinou M, Derby N, Grasperge B, Gettie A, Blanchard J, Kumar N, Roberts K, Robbiani M, Fernández-Romero JA, Zydowsky TM. A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy. J Control Release. 2015 Sep 10;213:57-68. doi: 10.1016/j.jconrel.2015.06.018. Epub 2015 Jun 17. PubMed PMID: 26091920; PubMed Central PMCID: PMC4683108. 18: Villegas G, Calenda G, Zhang S, Mizenina O, Kleinbeck K, Cooney ML, Hoesley CJ, Creasy GW, Friedland B, Fernández-Romero JA, Zydowsky TM, Teleshova N. In Vitro Exposure to PC-1005 and Cervicovaginal Lavage Fluid from Women Vaginally Administered PC-1005 Inhibits HIV-1 and HSV-2 Infection in Human Cervical Mucosa. Antimicrob Agents Chemother. 2016 Aug 22;60(9):5459-66. doi: 10.1128/AAC.00392-16. Print 2016 Sep. PubMed PMID: 27381393; PubMed Central PMCID: PMC4997862. 19: Kizima L, Rodríguez A, Kenney J, Derby N, Mizenina O, Menon R, Seidor S, Zhang S, Levendosky K, Jean-Pierre N, Pugach P, Villegas G, Ford BE, Gettie A, Blanchard J, Piatak M Jr, Lifson JD, Paglini G, Teleshova N, Zydowsky TM, Robbiani M, Fernández-Romero JA. A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV. PLoS One. 2014 Apr 16;9(4):e94547. doi: 10.1371/journal.pone.0094547. eCollection 2014. PubMed PMID: 24740100; PubMed Central PMCID: PMC3989196. 20: Kenney J, Aravantinou M, Singer R, Hsu M, Rodriguez A, Kizima L, Abraham CJ, Menon R, Seidor S, Chudolij A, Gettie A, Blanchard J, Lifson JD, Piatak M Jr, Fernández-Romero JA, Zydowsky TM, Robbiani M. An antiretroviral/zinc combination gel provides 24 hours of complete protection against vaginal SHIV infection in macaques. PLoS One. 2011 Jan 5;6(1):e15835. doi: 10.1371/journal.pone.0015835. PubMed PMID: 21246052; PubMed Central PMCID: PMC3016413.